Preclinical pharmacokinetics of MFGR1877A, a human monoclonal antibody to FGFR3, and prediction of its efficacious clinical dose for the treatment of t(4;14)-positive multiple myeloma

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 4, 2012, Pages 1071-1078

  Kamath, Amrita V ^a   Lu, Dan ^a   Gupta, Priyanka ^a   Jin, Denise ^a   Xin, Yan ^a   Brady, Ann ^a   Stephan, Jean Philippe ^a   Li, Hao ^a   Tien, Janet ^a   Qing, Jing ^a   Damico Beyer, Lisa A ^a  

^a GENENTECH INC   (United States)

Author keywords

FGFR3; Multiple myeloma; Pharmacokinetics; Xenograft model

Indexed keywords

ANTINEOPLASTIC AGENT; FIBROBLAST GROWTH FACTOR RECEPTOR 3; MFGR 1877A; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER LOCALIZATION; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG PROTEIN BINDING; EXPERIMENTAL MONKEY; FEMALE; HAPLORHINI; HUMAN; HUMAN CELL; MAXIMUM PLASMA CONCENTRATION; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PREDICTION; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; SPECIES COMPARISON;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; IMMUNOGLOBULIN G; MACACA FASCICULARIS; MICE; MICE, NUDE; MULTIPLE MYELOMA; NONLINEAR DYNAMICS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84859798123     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1807-5     Document Type: Article

References (19)

1. Eswarakumar VP, Lax I, Schlessinger J (2005) Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 16:139-149 (Pubitemid 40616112)
2. Beenken A, Mohammadi M (2009) The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 8:235-253
3. Chesi M, Nardini E, Brents LA et al (1997) Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet 16:260-264 (Pubitemid 27280209)
4. Chang H, Stewart AK, Qi XY et al (2005) Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma. Blood 106:353-355 (Pubitemid 40967212)
5. Paterson JL, Li Z, Wen XY et al (2004) Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma. Br J Haematol 124:595-603 (Pubitemid 38297091)
6. Trudel S, Ely S, Farooqi Y et al (2004) Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma. Blood 103:3521-3528 (Pubitemid 38525687)
7. Chen J, Lee BH, Williams IR et al (2005) FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies. Oncogene 24:8259-8267 (Pubitemid 43250918)
8. Chellaiah AT, McEwen DG, Werner S et al (1994) Fibroblast growth factor receptor (FGFR) 3. J Biol Chem 269:11620-11627
9. Qing J, Du X, Chen Y et al (2009) Antibody-based targeting of FGFR3 in bladder carcinoma and t (4; 14)-positive multiple myeloma in mice. J Clin Invest 119:1077-1079
10. Murgue B, Tsunekawa S, Rosenberg I et al (1994) Identification of a novel variant form of fibroblast growth factor receptor 3 (FGFR3-IIIb) in human colonic epithelium. Cancer Res 54:5206-5211 (Pubitemid 24313501)
11. Mould DR, Green B (2010) Pharmacokinetics and pharmacodynamics of monoclonal antibodies. Biodrugs 24(1):23-39
12. Deng R, Iyer S, Theil FP, Mortensen D, Fielder P, Prabhu S (2011) Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data. mAbs 3(1):61-66
13. Dedrick RL (1973) Animal scale-up. J Pharmacokinet Biopharm 1:435-461
14. Mahmood I (2004) Interspecies scaling of protein drugs: prediction of clearance from animals to humans. J Pharm Sci 93:177-185
15. Dirks NL, Meibohm B (2010) Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 49:633-659
16. Wang W, Prueksaritanont T (2010) Prediction of human clearance of therapeutic proteins: simple allometric scaling method revisited. Biopharm Drug Dispos 31(4):253-263
17. Ling J, Zhou H, Jiao Q, Davis HM (2009) Interspecies scaling of therapeutic monoclonal antibodies: initial look. J Clin Pharmacol 49(12):1382-1402
18. Berinstein NL, Grillo-Lopez AJ, White CA et al (1998) Association of serum Rituximab (IDEC-C2B8) concentration and antitumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 9(9):995-1001 (Pubitemid 28496709)
19. Li J, Levi M, Charoin J et al (2007) Rituximab exhibits a long half-life based on a population pharmacokinetic analysis in non-Hodgkin's lymphoma (NHL) patients. ASH annual meeting